CDIO (Cardio Diagnostics Holdings) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cardio Diagnostics Holdings 3-Year Revenue Growth Rate?

Cardio Diagnostics Holdings's Revenue per Share for the three months ended in Sep. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Cardio Diagnostics Holdings's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Cardio Diagnostics Holdings's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardio Diagnostics Holdings's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's 3-Year Revenue Growth Rate falls into.

Cardio Diagnostics Holdings 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Cardio Diagnostics Holdings (NAS:CDIO) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Cardio Diagnostics Holdings 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Cardio Diagnostics Holdings's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardio Diagnostics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardio Diagnostics Holdings Inc (NAS:CDIO) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

311 West Superior Street, Suite 444, Chicago, IL, USA, 60654

Website

https://www.cardiodiagnosticsinc.com

Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease.

Executives

Robert Philibert	director, 10 percent owner, officer: Chief Medical Officer	400 N. ABERDEEN, SUITE 900, CHICAGO IL 60642
Timur Dogan	officer: Chief Technology Officer	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Meeshanthini Dogan	director, 10 percent owner, officer: Chief Executive Officer	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Warren Hosseinion	director	C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Elisa V Luqman	officer: Chief Financial Officer	37 HARRISON DRIVE, NORTHPORT NY 11768
Khullani Abdullahi	officer: VP of Revenue and Strategy	400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Brandon Sim	director	C/O APOLLO MEDICAL HOLDINGS, INC., 1668 S. GARFIELD AVENUE, 3RD FLOOR, ALHAMBRA CA 91801
James Intrater	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Oded Levy	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Stanley K. Lau	director	C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Bd Holding, Inc.	10 percent owner	15 PROSPECT PLACE, IOWA CITY IA 52246
Jonathan Intrater	officer: CEO	223 PALMER STREET, PALMER MA 01069
Allan Liu	director	1600 PARKWOOD CIRCLE, STE 200, ATLANTA GA 30339-2119
Loren Mortman	director	207 EAST 74TH STREET, APARTMENT 10F, NEW YORK NY 10021
Mana Capital Llc	10 percent owner	8 THE GREEN, SUITE A, DOVER DE 19901